Thousands Find Relief with New NHS Migraine Tablets

The NHS has seen a rapid take-up of new CGRP-targeting migraine medications, with the regulator heralding them as life-changing for thousands. Atogepant and rimegepant, approved for use in England from 2023 and 2024 respectively, work by preventing the release of calcitonin gene-related peptide (CGRP), a key protein linked to migraine attacks. These are the first CGRP therapies available as easy-to-take tablets, offering a significant improvement over previous infusion or injection methods.

Patient testimonials highlight the profound impact of these pills. One individual, previously suffering a decade of migraines, reported a complete absence of headaches since starting atogepant, stating it has "restored my life." Previously, many relied on older preventive treatments like antidepressants or beta-blockers, which often had severe side effects and were not specifically designed for migraines.

In 2025, GPs in England prescribed atogepant or rimegepant to 22,800 individuals, more than triple the number in 2024. While these figures exclude hospital and specialist clinic prescriptions, they underscore the rapid adoption. However, access can be challenging, as NICE recommends these medications only after at least three other preventive treatments have failed, often requiring specialist initiation. This can lead to long NHS waiting times for patients.

Experts acknowledge the significant benefits these new tablets offer, improving patients' quality of life and ability to work or study. The challenge for the NHS lies in the cost of these medications, emphasizing the need for appropriate prescribing to ensure efficient resource allocation. A greater focus on identifying patients who would benefit most could expedite access to these transformative treatments.